Selected article for: "inhibitory activity and SARS CoV protease"
Author: Ferreira, Glaucio Monteiro; Kronenberger, Thales; Tonduru, Arun Kumar; Hirata, Rosario Dominguez Crespo; Hirata, Mario Hiroyuki; Poso, Antti
Title: SARS-COV-2 M(pro) conformational changes induced by covalently bound ligands
  • Cord-id: pxiqssym
  • Document date: 2021_9_13
    • ID: pxiqssym
    Snippet: SARS-CoV-2’s main protease (M(pro)) interaction with ligands has been explored with a myriad of crystal structures, most of the monomers. Nonetheless, M(pro) is known to be active as a dimer but the relevance of the dimerization in the ligand-induced conformational changes has not been fully elucidated. We systematically simulated different M(pro)-ligand complexes aiming to study their conformational changes and interactions, through molecular dynamics (MD). We focused on covalently bound liga
    Document: SARS-CoV-2’s main protease (M(pro)) interaction with ligands has been explored with a myriad of crystal structures, most of the monomers. Nonetheless, M(pro) is known to be active as a dimer but the relevance of the dimerization in the ligand-induced conformational changes has not been fully elucidated. We systematically simulated different M(pro)-ligand complexes aiming to study their conformational changes and interactions, through molecular dynamics (MD). We focused on covalently bound ligands (N1 and N3, ∼9 μs per system both monomers and dimers) and compared these trajectories against the apostructure. Our results suggest that the monomeric simulations led to an unrealistically flexible active site. In contrast, the M(pro) dimer displayed a stable oxyanion-loop conformation along the trajectory. Also, ligand interactions with residues His41, Gly143, His163, Glu166 and Gln189 are postulated to impact the ligands' inhibitory activity significantly. In dimeric simulations, especially Gly143 and His163 have increased interaction frequencies. In conclusion, long-timescale MD is a more suitable tool for exploring in silico the activity of bioactive compounds that potentially inhibit the dimeric form of SARS-CoV-2 M(pro). Communicated by Ramaswamy H. Sarma

    Search related documents:
    Co phrase search for related documents
    • acceptor atom donor and active site: 1
    • active conformation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • active conformation and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active conformation and loop conformation: 1, 2
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and long range: 1, 2, 3, 4, 5
    • active site and long timescale: 1
    • active site and long timescale simulation: 1
    • active site and loop conformation: 1, 2
    • active site conformation and acute respiratory syndrome: 1, 2, 3, 4
    • active site conformation and acute respiratory syndrome coronavirus: 1, 2, 3, 4
    • activity dimerization and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activity dimerization and acute respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activity dimerization and long range: 1, 2
    • acute respiratory syndrome and local expansion: 1
    • acute respiratory syndrome and long range: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long timescale: 1
    • acute respiratory syndrome and loop conformation: 1, 2, 3